Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) (RMO)
a Single Arm,Multi-center,Phase II Clinical Trial of Combined Therapy for Orelabrutinib,Rituximab and Methotrexate(RMO)in Newly-diagnosed Primary Center Nervous System Lymphoma(PCNSL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: wenrong huang, Dr
- Phone Number: 861066947177
- Email: huangwr301@163.com
Study Contact Backup
- Name: shihua zhao, Dr
- Phone Number: 861066947178
- Email: zhaoshihua307@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100071
- Recruiting
- Hospital 307
-
Contact:
- shihua zhao, Dr.
- Phone Number: 861066947167
- Email: zhaoshihua307@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- primary central nervous system diffuse large B-cell lymphoma histologically confirmed by brain biopsy;
- Aged 18-70 years
- Signature of informed consent;
- At least one measurable lesion;
- Neutropile≥1.5X109/L,Hemoglobin≥80g/L,Platelets≥75X109/L,Billrubin<2XULN,ALT<4XULN,AST4XULN
- The expected survival time is at least 3 months
Exclusion Criteria:
- Those who have contraindications to any of the components in the Orelabrutinib,Rituximab and HD-MTX
- History of other malignancies that may affect the compliance of the research protocol or the analysis of the results
- Severe cardiac insufficiency
- Other antitumor treatments were used
- Human immunodeficiency virus(HIV)antibody is positive
- Pregnant or lactating women
- Researchers consider if anyone not suitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Orelabrutinib,Rituximab and Methotrexate
Rituximab 375 mg/m2 d1; MTX 3.5mg/m2,d2; Orelabrutinib 150g/day; every three week/cycle.
|
Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma.
The response will be evaluated every 2 cycles.
Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction.
The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens.
After total 6 induction cycles, the investigators evaluate the efficiency again.
After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue.
The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance.
The patients with SD or PD will receive salvage regimen.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
primary endpoint
Time Frame: Enrollment is expected to last for two year, followed up for five years
|
Objective response rate(ORR) is the primary endpoint
|
Enrollment is expected to last for two year, followed up for five years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
secondary endpoints
Time Frame: Enrollment is expected to last for two year, followed up for five years
|
Complete rate(CR)、progression free survival(PFS)、overall survival(OS) are the secondary endpoints
|
Enrollment is expected to last for two year, followed up for five years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Rituximab
- Methotrexate
Other Study ID Numbers
Other Study ID Numbers
- 307-947168-88
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.